Warning! GuruFocus detected
1 Severe warning sign
with 4168.
Try a 7-Day Free Trial
to check it out.
What is a stock summary page? Click here for an overview.
Business Description
GlycoNex Inc
NAICS : 325412
SIC : 2834
ISIN : TW0004168000
Description
GlycoNex Inc is a Taiwan based company engaged in the development of cancer drugs from the combination of glycosphingolipid antigen and human monoclonal antibody technologies. It has a panel of antibodies that targets various carbohydrate antigens. The antibodies are cloned from hybridoma, engineered to improve stability, and can serve as reagents with applications that include ELISA, Western blot, flow cytometry, and TLC immunostaining. The Company also provides antibody research services to its academic and industrial clients. The other services provided by the firm include functional evaluation and antibody engineering. The company has two segments which are antibody new drugs and exclusive investment. It earns the majority of its revenue from the antibody new drugs segment.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 491.23 | |||||
| Equity-to-Asset | 0.8 | |||||
| Debt-to-EBITDA | -0.01 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 3.42 | |||||
| Beneish M-Score | 1.49 | |||||
| WACC vs ROIC | ||||||
Growth Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 34.4 | |||||
| 3-Year EBITDA Growth Rate | -8.6 | |||||
| 3-Year EPS without NRI Growth Rate | -6 | |||||
| 3-Year FCF Growth Rate | -16 | |||||
| 3-Year Book Growth Rate | -11.4 |
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 32.26 | |||||
| 9-Day RSI | 27.91 | |||||
| 14-Day RSI | 26.6 | |||||
| 3-1 Month Momentum % | 0.42 | |||||
| 6-1 Month Momentum % | -7.36 | |||||
| 12-1 Month Momentum % | -6.64 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.82 | |||||
| Quick Ratio | 1.82 | |||||
| Cash Ratio | 1.67 | |||||
| Days Sales Outstanding | 14.47 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -3.5 | |||||
| Shareholder Yield % | 5.96 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 49.8 | |||||
| Operating Margin % | -1674.15 | |||||
| Net Margin % | -1562.51 | |||||
| FCF Margin % | -1749.84 | |||||
| ROE % | -19.83 | |||||
| ROA % | -15.98 | |||||
| ROIC % | -23.09 | |||||
| 3-Year ROIIC % | -178.19 | |||||
| ROC (Joel Greenblatt) % | -27.15 | |||||
| ROCE % | -19.25 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 119.25 | |||||
| PB Ratio | 1.68 | |||||
| Price-to-Tangible-Book | 1.67 | |||||
| EV-to-EBIT | -5.8 | |||||
| EV-to-EBITDA | -6.86 | |||||
| EV-to-Revenue | 88.5 | |||||
| EV-to-FCF | -5.31 | |||||
| Price-to-GF-Value | 0.48 | |||||
| Price-to-Median-PS-Value | 0.07 | |||||
| Price-to-Net-Current-Asset-Value | 8.26 | |||||
| Price-to-Net-Cash | 10.13 | |||||
| Earnings Yield (Greenblatt) % | -17.21 | |||||
| FCF Yield % | -14.77 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
GlycoNex Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil NT$) | 14.701 | ||
| EPS (TTM) (NT$) | -2.12 | ||
| Beta | -0.55 | ||
| 3-Year Sharpe Ratio | -0.41 | ||
| 3-Year Sortino Ratio | -0.56 | ||
| Volatility % | 22.45 | ||
| 14-Day RSI | 26.6 | ||
| 14-Day ATR (NT$) | 0.715257 | ||
| 20-Day SMA (NT$) | 18.41 | ||
| 12-1 Month Momentum % | -6.64 | ||
| 52-Week Range (NT$) | 15.6 - 31.85 | ||
| Shares Outstanding (Mil) | 108.21 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
GlycoNex Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
GlycoNex Inc Stock Events
| Event | Date | Price (NT$) | ||
|---|---|---|---|---|
| No Event Data | ||||
GlycoNex Inc Frequently Asked Questions
What is GlycoNex Inc(ROCO:4168)'s stock price today?
The current price of ROCO:4168 is NT$16.10. The 52 week high of ROCO:4168 is NT$31.85 and 52 week low is NT$15.60.
When is next earnings date of GlycoNex Inc(ROCO:4168)?
The next earnings date of GlycoNex Inc(ROCO:4168) is .
Does GlycoNex Inc(ROCO:4168) pay dividends? If so, how much?
GlycoNex Inc(ROCO:4168) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers